BioScrip, a provider of specialty pharmacy products and services, has appointed David Froesel, Jr as executive vice president (EVP), chief financial officer (CFO) and treasurer. Froesel will replace Stanley Rosenbaum, who will be leaving the company prior to year-end.
Froesel was a key member of the executive team at Omnicare for almost 14 years, where he served as senior vice president (SVP) and CFO from March 1996 until his retirement in December 2009. During Froesel’s time at Omnicare, the company completed over 100 acquisitions, raised in excess of US$7bn of capital through the bank and public markets and consistently generated significant positive operating cash flow. Additionally, he has extensive experience in restructuring, merger integration and cost reduction activities.
Prior to joining Omnicare, Froesel was employed for 18 years at Mallinckrodt Group, a US$2.5bn healthcare and specialty chemical company. From May 1993 to February 1996, he was vice president of finance and administration at Mallinckrodt Veterinary, a subsidiary. From July 1989 to April 1993, he was worldwide corporate controller of Mallinckrodt Medical, another subsidiary. He received a BS in Accounting from the University of Missouri-St Louis and an MS in Accounting from St Louis University and is a certified public accountant (CPA).
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.